RNA interference and micro-
RNA–oriented therapy in cancer: rationales, promises, and challenges

T.F. Duchaine PhD,* and F.J. Slack PhD†

ABSTRACT

The discovery that RNA interference (RNAi) and its functional derivatives, small interfering RNAs (si-RNAs) and micro-RNAs (mi-RNAs) could mediate potent and specific gene silencing has raised high hopes for cancer therapeutics. The prevalence of these small (18–25 nucleotide) non-coding RNAs in human gene networks, coupled with their unique specificity, has paved the way for the development of new and promising therapeutic strategies in re-directing or inhibiting small RNA phenomena.

Three strategies are currently being developed:

- De novo RNAi programming using synthetic siRNAs to target the expression of genes
- Strengthening or recapitulation of the physiologic targeting of messenger RNAs by specific miRNAs
- Sequence-specific inhibition of miRNA functions by nucleic acid analogs

Each strategy, currently being developed both in academia and in industry, holds promise in cancer therapeutics.

KEY WORDS
Cancer therapy, siRNA, miRNA, RNAi therapy, oncomirs, nucleic acid analogs, tumour-suppressor miRNAs

1. INTRODUCTION

These are very interesting times in the field of gene regulation as it affects development and cancer. Since the late 1990s, the tenets of the “central dogma” have undergone revision as scientists began to appreciate that RNAs, by themselves, play key regulatory roles.

Leading the charge in this revolution are the small (18–25 nucleotide) non-coding RNAs called “small interfering” RNAs (siRNAs) and micro-RNAs (miRNAs), which direct RNA interference (RNAi) phenomena. The siRNAs and miRNAs are newly discovered regulatory molecules that control a variety of biologic processes, including development, metabolism, and aging 1–3. The miRNAs often bind to complementary sequences in the 3′ untranslated regions of target messenger RNAs (mRNAs) to repress target gene expression; the siRNAs can bind to any complementary sequence in a target mRNA. Importantly, functional roles have been demonstrated for miRNAs in cancer 4,5, and the potential exists to use similar molecules as cancer therapeutics.

The present review outlines the underlying rationales for considering small RNA therapeutics. Although most of the attention has been given to the use of siRNAs to inhibit gene function, we provide a broader overview and include novel and emerging strategies that are instead based on miRNAs. We highlight the potential of each strategy for cancer treatment and summarize the challenges that need to be overcome to fully harness RNAi- and miRNA-based therapies.

2. THE MOLECULAR BASIS FOR siRNA- AND miRNA-MEDIATED SILENCING

The silencing mediated by RNAi and miRNA is initiated when the double-stranded RNA (dsRNA)–specific type III endonuclease, Dicer, “recognizes” a dsRNA substrate. Processing by Dicer and its accessory proteins yields 18- to 25-nucleotide heteroduplex small RNAs (either siRNAs or miRNAs, depending on their origin). The miRNAs are usually endogenously transcribed; the siRNAs often derive from exogenous sources such as viruses 6,7. One of the strands of the small RNA duplex is selected, loaded into Argonaute proteins, and assembled into an effector complex such as the RNA-induced silencing complex (RISC).

Copyright © 2009 Multimed Inc.
The other strand is often cleaved or unwound and degraded. A key feature for the use of RNAi in therapy is that the RISC can be directly programmed by exogenous mature siRNAs or miRNAs. In effect, this programming bypasses cleavage by Dicer and the interferon response triggered by dsRNAs larger than 30 bp in mammalian cells. Generally, when a siRNA fully pairs with a target mRNA, the result is rapid and specific cleavage, an activity named “slicer.”

In contrast to siRNAs, miRNAs normally originate from gene-encoded precursor transcripts that are processed into precursor miRNAs. Those precursors fold as hairpins and serve as Dicer substrates. Embedded within the RISC, mature miRNAs pair only partially with their mRNA targets, thereby directing translation inhibition or reducing the stability of their target.

The gene-targeting information is non-symmetrically encoded within mature siRNAs or miRNAs. The 5’ portion of the miRNA at positions 2–7 is thought to encode the most important determinant to direct base-pairing with mRNA targets. This portion (called the “core,” “nucleus,” or “seed” sequence) is most commonly conserved; it defines paralogous and orthologous families of miRNAs. Structural studies show a tight coordination of this 5’ determinant within the Argonaute proteins. The 3’ part of the miRNA or siRNA is more amenable to chemical modifications, some of which occur naturally.

3. THE BIOLOGIC IMPLICATIONS OF miRNAs FOR CANCER

To evaluate the potential of small RNAs in cancer therapy, an appreciation of how extensively they are tied to the normal cell’s gene regulation networks is essential. In human cells, miRNAs are estimated to account for more than 1000 genes (approximately 3% of the total estimated number of genes) and to exert direct negative regulative pressure on more than 30% of the entire coding gene set. Accordingly, miRNAs are known to regulate genes implicated in a wide range of cellular functions in development and homeostasis. For example, the first two known miRNAs—lin-4 and let-7—control timing of cell differentiation during development. In let-7 mutants, stem cells in the skin frequently fail to terminally differentiate, electing instead to divide again. Such cellular events are the defining hallmarks of cancer.

Because misregulation of genes that control cell proliferation and cell fate often contribute to cancer development, miRNAs are unsurprisingly also implicated in cancer biology. Early evidence in humans indicates that miRNA loci are associated with chromosome sites that are often deleted or amplified, and whose expression is dramatically altered during the onset of cancer. Intense current research aims to precisely delineate the functions of miRNAs in transformation and tumour growth. In an increasing number of reports, miRNAs are now being shown to be capable of acting as bona fide tumour suppressors or oncogenes, bringing about a major shift in the landscape of cancer research.

4. siRNA- AND miRNA-BASED THERAPEUTIC STRATEGIES

The chemical properties of the various miRNAs vary little, and yet, through the sequences that they encode, they direct completely distinct activities. At least three distinct overall strategies were adopted early on for siRNA- and miRNA-based therapies. Each one aims (reasonably) to exploit the sequence-directed properties of the small RNAs:

- First, de novo reprogramming of the RNAi machinery can be utilized against a gene that has deleterious effects. (Figure 1, panel 1).
- Second, a physiologic miRNA–mRNA pair could be reproduced by programming the RISC using a known, beneficial miRNA—for example, a tumour suppressor miRNA (Figure 1, panel 2).
- Third, a nonhydrolyzable mimic of an RNA target could be generated to effectively sequester deleterious miRNAs from their pro-oncogenic functions (Figure 1, panel 3).

4.1 Harnessing RNAi: De Novo Programming with siRNAs

Perhaps the simplest and the most direct therapeutic strategy involving RNAi is to harness and redirect its machinery against a detrimental miRNA target. It therefore comes as no surprise that this strategy is by far the most advanced in clinical trials. The siRNA-directed targeting of genes is currently being developed as a potential therapy in a great number of diseases. The keys to this strategy are identification of a functional and effective RNAi target and optimization of the targeting process. The strategy can include, but it not limited to, knowing the uniqueness of the siRNA’s target sequence in the genome, optimizing its loading into the RISC, obtaining a measure of the accessibility of the siRNA target site (structure, protein–RNA interactions), and possibly even adding tolerated covalent modifications to the siRNA. In addition, and common to each RNAi- or miRNA-based therapy, is the need to deliver the RNA molecule or analog to the correct tissue and mRNA target (see the “Challenges” subsection).

Many siRNA-based therapies are under development, but surprisingly few are directed at oncogenic targets. Among the cancer-directed approaches is the targeting of pleiotrophin, which effectively reduced tumour growth in mouse xenograft models of glioblastoma multiforme. Another initiative of interest is the successful targeting of the Ews–Fli1 fusion oncoprotein in mouse models of metastatic Ewing sarcoma.
4.2 Tilting the Balance: miRNAs As Drugs

A second potential approach in RNAi-based cancer therapy is to deliver a mature or engineered miRNA precursor to specific biologic compartments to affect its known and physiologic miRNA targets. In effect, this strategy aims at the restoration, the strengthening, or the ectopic rewiring of known miRNA-target circuitry. In contrast with the de novo programming approach, this strategy relies heavily on prior and extensive characterization of the biologic functions of the miRNA of interest. The idea would be

- to know the identity of the physiologic targets of the miRNA of interest, and
- to have a good idea of how the associated genes are embedded within their genetic network.

This second aspect is important, considering that miRNAs often function as parts of loops (feedback and feed-forward) between gene networks. (For examples, see Li et al. and Xu et al.)

One miRNA that fits each of these requirements is let-7. Overexpression of let-7 in a mouse model of lung cancer involving an activated K-ras allele suppresses activating oncogenic ras mutations just as such overexpression does in C. elegans. Signalling by ras plays an important role in radiosensitivity, and radiotherapy is one of the three primary modalities used in combatting cancer. However, many cancers, including lung cancer, are radioresistant. Because let-7 represses ras, let-7 overexpression has been proposed to be a possible cause of radiosensitivity, a hypothesis that indeed proved to be the case in both lung cancer cells and in an in vivo C. elegans model. These data provided the first evidence that miRNAs could potentially augment current cancer therapies.

An even more recent publication reported the use of a similar strategy—named “mirna replacement therapy”—aimed at restoring mir26a expression in hepatocellular carcinoma. When delivered in a mouse model using adeno-associated virus, this miRNA was able to suppress proliferation and induce apoptosis, which resulted in inhibition of hepatocellular carcinoma progression.

4.3 Sequence-Directed Inhibition: miRNAs As Drug Targets

Where the strategies already discussed are based on programming of the RISC, a third promising strategy involves inhibition of the endogenous functions of well-characterized miRNAs. This inhibition is accomplished by “base-pairing”: using complementary nucleic acid analogs to block the unique signature of small RNAs (mainly the “seed”). One major advantage of this strategy is that the constraints required to contact or base-pair with a miRNA sequence are likely to be much looser than the requirements to fit within the tightly coordinated binding pocket of the RISC and to act as a functional RNAi component. These looser constraints in turn allow for greater chemical and covalent modifications to be made to the backbone of the analog inhibitor to change its stability, miRNA-inhibiting properties, and even its pharmacokinetics and biodistribution. At this stage, the frontrunners of these modifications are the locked nucleic acids (LNAs) and 2′-O-methyl and 2′-O-methoxymethyl. In addition to combinations of these modifications, analogs such as the “antagomirs” (miRs) are modified with phosphorothioate substitutions on the backbone and with cholesterol conjugation.

A recent and successful example of this overall strategy is the in vivo inhibition of mir122 miRNA using a 15-nucleotide LNA-bearing analog. The liver-specific mir122 has been implicated in cholesterol and lipid metabolism and has been linked to replication of hepatitis C virus (HCV) in vitro. A recent study by Elmen and colleagues is the first to report inhibition of miRNAs by analogs in vivo in nonhuman primates. Reduction of mature mir122 levels in the liver was accompanied by a substantial and reversible reduction in plasma cholesterol,
without inducing any detectable sign of toxicity or tissue damage. This work raised the possibility that miR122 could be targeted in chronically infected HCV patients, for example, which could in turn reduce the associated risk of carcinoma. In a broader sense, this work highlights the potential of targeting miRNAs using LNA analogs in therapy, with low toxicity and high specificity.

Although the use of miRNA inhibitors is only starting to emerge as a therapeutic strategy, an important number of studies have reported miRNA targeting by analogs in cell culture or mouse models. Successfully targeted and cancer-relevant miRNAs include miR16; miR21; miR34a, b, and c; miR29b; miR221/222; and the 17 to approximately 92 cluster of miRNAs individually—and the list is rapidly growing (see Stenvang et al. and references therein). Considering the role of miRNAs in cancer, the low toxicity of LNA in primates, and the feasibility of efficient targeting of miRNAs in vivo, the potential impact of this strategy is immense.

5. CHALLENGES

By far the most important challenge faced by researchers developing therapeutic strategies based on RNAi is the means to deliver the siRNAs, miRNAs, or analogs to the correct cells in the organism. Intrinsically, RNAs are polar and labile, and their pharmacokinetic properties are completely alien to most of the desired cellular destinations. The stability of the RNA molecule can be greatly enhanced by blocking the 2′-hydroxy group of ribonucleotides and modifying the phosphodiester backbone, but delivery must be tailored and optimized for each tissue and cellular target. A few early reports describing direct delivery of naked, unmodified RNA molecules to the target tissue appeared successful, one case being siRNAs targeting respiratory syncytial virus to the lung. In addition, siRNA targeting of vascular endothelial growth factors α and 1 in age-related macular degeneration has been reported. However, recent work by Kleinman et al. called the reasons for these findings into question when those authors reported that at least some of the anti-angiogenesis virtues of the siRNA treatment were independent of its sequence. Instead, efficacy appeared to depend on the Toll-like receptor 3–triggered induction of the interferon γ response. That study was seen by some as a setback for siRNA-based therapies. For others, it meant simply that RNAi- or nucleic acid–based therapy in general requires additional fine-tuning to escape the innate immune response. Part of the solution is likely already underway, because an important variety of synthetic material has been established and successfully used for siRNA or nucleic acid delivery. The efficient strategies reported range from direct conjugation of cholesterol and nucleic acids or analogs, to complexation or coating with liposomes or polyelastomers. (For a recent and thorough review on this topic, see Whitehead et al.

Another important concern for RNAi and miRNA-based therapy is the unintentional targeting of miRNAs, termed “off-targets.” This effect has been well characterized using microarray studies of siRNA-transfected cells, in which expression in an important number of genes declined with increased concentration of siRNAs. It is also thought that ectopic expression of miRNAs can result in a related effect. Selective pressure normally disfavours the presence of sequences complementary to a miRNA “seed” in non-targets and co-expressed miRNAs—a phenomenon termed “avoidance.” Ectopically expressed or overexpressed miRNAs in therapy can therefore potentially find sequences that are avoided under physiologic conditions.

In part, the delivery and off-target issues of siRNA- and miRNA-based therapies are linked. Ideally, the means to deliver these nucleic acids, or their analogs, to cells would proceed so efficiently as to maintain low administered concentrations. More efficient delivery should reduce the number of cells exposed, favour uptake, and reduce the potential for off-target effects, hence maintaining a suitable therapeutic index.

6. CONCLUSIONS

Although the field of RNAi is still an emerging one, the benefits of understanding the roles of miRNAs and siRNAs in cancer are potentially enormous, not only for their roles as cancer loci, but also because for the growing likelihood that small RNAs can be used as therapeutics in treating cancer itself.

7. ACKNOWLEDGMENTS

We thank Noriko Uetani for artistic and conceptual help with the figure. We also thank Anthoula Lazaris and Ahilya Nirvana Sawh for helpful comments on the manuscript.

This work was supported by grants from the Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council of Canada, and a Chercheur–Boursier Junior 1 Award to TFD. FJS was supported by a grant from the U.S. National Institutes of Health (CA131301-01A1).

8. REFERENCES

1. Banerjee D, Slack F. Control of developmental timing by small temporal RNAs: a paradigm for RNAi-mediated regulation of gene expression. Bioessays 2002;24:119–29.
2. Grosshans H, Slack FJ. Micro-RNAs: small is plentiful. J Cell Biol 2002;156:17–22.
3. Niwa R, Slack FJ. The evolution of animal microRNA function. Curr Opin Genet Dev 2007;17:145–50.
RNAi AND miRNA-ORIENTED THERAPY

1. Cullen BR. RNA interference therapeutics. Nat Rev Drug Discov 2006;5:701–11.
2. Tomari Y, Gomi K, Arimura K, Murakami A, Tatsumi T, Tuschl T. The argonautes: a family of RNA helicases with a novel RNA-dependent ATPase activity. RNA 2003;9:1341–52.
3. Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell 2009;136:642–55.
4. Bohm M, Slack F. A developmental timing microRNA and its target regulate life span in C. elegans. Science 2005;310:1954–7.
5. Johnson SM, Grosshans H, Shingara J, et al. "RAS" is regulated by the let-7 microRNA family. Cell 2005;120:635–47.
6. Filipowicz W. RNAi: the nuts and bolts of the RISC machine. Cell 2005;122:17–20.
7. Jaskiewicz L, Filipowicz W. Role of Dicer in posttranscriptional RNA silencing. Curr Top Microbiol Immunol 2008;320:77–97.
8. Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell 2009;136:642–55.
9. Pratt AJ, Macrae IJ. The RNA induced silencing complex: a versatile gene-silencing machine. J Biol Chem 2009;[Epub ahead of print].
10. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNA mediate RNA interference in cultured mammalian cells. Nature 2001;411:494–8.
11. Liu J, Carmell MA, Rivas FV, et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science 2004;305:1437–43.
12. Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol 2009;10:126–39.
13. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by miRNAs: are the answers in sight? Nat Rev Genet 2009;10:92–14.
14. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005;120:15–20.
15. Wang Y, Juranek S, Li H, Sheng G, Tuschl T, Patel DJ. Structure and function of an Argonaute silencing complex with a seed-containing guide RNA and target RNA duplex. Nature 2008;456:921–6.
16. Lewis BP, Shih IH, Jones–Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 2003;115:787–98.
17. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281–97.
18. Reinhart B, Slack F, Basson M, et al. The 21 nucleotide let-7 RNA regulates C. elegans developmental timing. Nature 2000;403:901–6.
19. Calin GA, Sevignani C, Dumitrau CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004;101:2999–3004.
20. Meltzer PS. Cancer genomics: small RNAs with big impacts. Nature 2005;435:745–6.
21. Voorhoeve PM, le Sage C, Schrier M, et al. A genetic screen implicates mir-372 and mir-373 as oncogenes in testicular germ cell tumors. Cell 2006;124:1169–81.
22. O’Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs participate in the master regulatory network that controls cell cycle progression. J Biol Chem 2005;280:839–46.
23. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature 2005;435:828–33.
24. Calin GA, Croce CM. MicroRNA–cancer connection: the beginning of a new tale. Cancer Res 2006;66:7390–4.
25. de Fougerolles A, Vromlocher HP, Maranganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 2007;6:443–53.
26. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009;8:129–38.
27. Grzelinski M, Urban–Klein B, Martens T, et al. RNA interference–mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vitro exerts antitumoural effects in glioblastoma xenografts. Human Gene Ther 2006;17:751–66.
28. Hu–Lieskovsan J, Heidel JD, Bartlett DW, Davis ME, Triche TJ. Sequence-specific knockdown of EWS–Fli1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing’s sarcoma. Cancer Res 2005;65:8984–92.
29. Weidhaas JB, Babar I, Nallur SM, et al. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res 2007;67:11111–6.
30. Slack FJ, Weidhaas JB. MicroRNAs as a potential magic bullet in cancer. Future Oncol 2006;2:73–82.
31. Li X, Cassidy JJ, Reimke CA, Fischboeck S, Carthew RW. A microRNA imparts robustness against environmental fluctuation during development. Cell 2009;137:273–82.
32. Xu N, Papagiannakopoulos T, Pan G, Thomson JA, Kosik KS. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell 2009.
33. Esquela–Kerscher A, Trang P, Wiggins JF, et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 2008;7:759–64.
34. Kumar MS, Erkeland SJ, Pester RE, et al. Suppression of non-small cell lung tumor growth by the let-7 microRNA family. Proc Natl Acad Sci U S A 2008;105:3903–8.
35. Kota J, Chivukula RR, O’Donnell KA, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009;137:1005–17.
36. Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with “antagomirs.” Nature 2005;438:685–9.
37. Meister G, Landthaler M, Dorsett Y, Tuschl T. Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing. RNA 2004;10:544–50.
38. Hutvagner G, Simard MJ, Mello CC, Zamore PD. Sequence-specific inhibition of small RNA function. PLoS Biol 2004;2:E98.
39. Davis S, Propp S, Freier SM, et al. Potent inhibition of microRNA in vivo without degradation. Nucleic Acids Res 2009;37:70–7.
40. Davis S, Lollo B, Freier S, Esau C. Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res 2006;34:2294–304.
41. Elmen J, Lindow M, Schutz S, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008;452:896–9.
42. Chang J, Guo JT, Jiang D, Guo H, Taylor JM, Block TM. Liver-specific microRNA mir-122 enhances the replication of hepatitis C virus in nonhepatic cells. J Virol 2008;82:8125–33.
43. Stenvang J, Silahlartoeglou AN, Lindow M, Elmen J, Kauppinen S. The utility of LNA in microRNA-based cancer diagnostics and therapeutics. Semin Cancer Biol 2008;18:89–102.
44. DeVincenzo J, Cehelsky JE, Alvarez R, et al. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res 2008;77:225–31.
45. Fattal E, Bochat A. Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA. Adv Drug Deliv Rev 2006;58:1203–23.
46. Kleinman ME, Yamada K, Takeda A, et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008;452:591–7.
47. Jackson AL, Linsley PS. Noise amidst the silence: off-target effects of siRNAs? Trends Genet 2004;20:521–4.
48. Jackson AL, Bartz SR, Schelter J, et al. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 2003;21:635–7.
49. Farh KK, Grimson A, Jan C, et al. The widespread impact of mammalian microRNAs on mRNA repression and evolution. Science 2005;310:1817–21.

Correspondence to: Thomas F. Duchaine, Goodman Cancer Centre and Department of Biochemistry, McGill University, 1160 Avenue des Pins West, Montreal, Quebec H3A 1A3.

* Goodman Cancer Centre and Department of Biochemistry, McGill University, Montreal, QC.
† Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, CT, U.S.A.